Concepedia

Author

Roswitha Forstpointner

Ludwig-Maximilians-Universität MünchenORCID

Also Known As

Forstpointner, R, Forstpointner, Roswitha, R Forstpointner, R. Forstpointner, Roswitha Forstpointner

66

Publications

3.8K

Citations

20

H-Index

20

Concepts

All Affiliations

Ludwig-Maximilians-Universität MünchenKlinikum OldenburgUniversity Hospital Schleswig-HolsteinUniversity of LübeckLMU Klinikum
RF

About

Roswitha Forstpointner is an author at Ludwig-Maximilians-Universität München specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

732

2

Immunology

5

5

488

3

Pathology

5

5

250

4

Health Sciences

4

4

98

5

Surgical Oncology

1

1

34

Roswitha Forstpointner

×

22

Publications

3.6K

Citations

19

H-Index

YearCitations

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Roswitha Forstpointner

Blood

2004

579

Treatment of Older Patients with Mantle-Cell Lymphoma

Hanneke C. Kluin‐Nelemans, Eva Hoster, Olivier Hermine,

New England Journal of Medicine

2012

511

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling,

Blood

2006

464

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A. Herrmann, Eva Hoster, Thomas Zwingers,

Journal of Clinical Oncology

2008

394

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Eva Hoster, Jan Walewski,

The Lancet

2016

390

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

Eva Hoster, Andreas Rosenwald, Françoise Berger,

Journal of Clinical Oncology

2016

344

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Wolfgang Hiddemann, Anna Maria Barbui, Miguel Canales,

Journal of Clinical Oncology

2018

226

Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network

Eva Hoster, Wolfram Klapper, Olivier Hermine,

Journal of Clinical Oncology

2014

160

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada,

The Lancet Oncology

2018

152

Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

Olivier Hermine, Eva Hoster, Jan Walewski,

Blood

2010

65

Page 1